Guide · Step 8 of 8 · Clinical evidence
Will your regulatory team and KOLs actually back this?
This is the question that decides whether a healthcare campaign ever ships, and whether the people you need to carry it are still in the room twelve months later. It is also the question most marketing teams answer too late, after the creative is already approved and the budget is already committed.
The Trust Hierarchy
From the manuscript · Ch 8
Highest trust. A respected clinician saying it carries weight no other source replicates. Earned through long relationships and demonstrated independence.
Citable, defensible, slow. Trust transfers from the journal’s standing more than the brand’s. Required for any contested claim.
Quietly load-bearing. A claim that maps cleanly to a published guideline rarely needs re-litigating. One that contradicts one will be re-litigated forever.
Consultant, analyst, professional society staff. Useful when the brand can’t speak directly. Loses trust quickly if perceived as paid.
Lowest trust by default. Earns trust only when consistent with the four layers above. Cannot substitute for them.
Trust flows top to bottom. A campaign carried by Level 1 + 2 survives scrutiny. A campaign carried by Level 5 alone gets re-litigated every conversation.
The wrong path
Bringing in regulatory and KOLs after the creative is locked.
The default sequence in most healthcare commercial teams runs in the wrong order. Marketing builds the campaign. Creative gets approved. Budget gets committed. Then the regulatory team is asked for sign-off and the KOLs are asked to lend their names. By the time the conversation with the people who decide whether the campaign survives contact with reality begins, the campaign is already too expensive to change.
What follows is a slow grind of compromise. Claims get softened until they don’t differentiate. Voices get pulled because the KOL doesn’t want their name on language they didn’t help write. The campaign ships later than planned, with less impact than promised, into a window of attention that has already moved on. Worst case, the KOL community quietly starts distancing itself — meaning the next campaign starts from a worse position than this one.
The fix is to choreograph the regulatory and clinical voices in from day one. The Trust Hierarchy decides what claim each level can carry. The messaging house anchors the language to the evidence before any creative gets near it. The KOL conversations happen at the strategy stage, not the sign-off stage. Done in the right order, regulatory and KOL involvement is an accelerant. Done in the wrong order, it’s the bottleneck.
The right path
Five moves to make regulatory and KOLs the accelerant.
The order-of-operations that turns the regulatory and clinical voices from blockers into compounders. None of these moves are expensive on their own; sequenced together they are the moat that no generic demand-gen agency can cross.
01
Bring regulatory in at strategy, not at sign-off
The regulatory lead should be in the room when the campaign is being scoped, not when it’s being approved. Their constraints are inputs, not blockers. Treat them as constraints and the campaign moves; treat them as blockers and the campaign stalls.
02
Map every claim against the Trust Hierarchy
For each claim the campaign needs to make, identify which level of the hierarchy can carry it. Some claims need a Level 1 KOL. Some need a Level 2 publication. Some can sit at Level 5. Misallocating which level carries what is the most-common single error in healthcare marketing.
03
Build the messaging house before the creative brief
Claims, evidence, qualifiers, contraindications - written down, signed off, locked. The creative team works inside the boundaries this defines. Without a messaging house, every creative round re-litigates the same regulatory questions and the project ages by months.
04
Choreograph the KOL conversations early
By the time you ask a KOL to put their name on something, they should already have helped shape it. Co-authorship, advisory boards, pre-publication review - these are not nice-to-haves; they are the mechanism by which trust transfers from clinician to brand.
05
Plan for the long arc, not the campaign
A KOL relationship is a multi-year asset. A single campaign that burns it costs more than the campaign saved. Healthcare commercial leaders who think in single-campaign cycles overspend on advocates and underdeliver on advocacy. Plan the relationship arc; let campaigns sit inside it.
The decision
For each claim - which trust level should carry it?
A useful exercise to run before any campaign ships: take every claim the creative wants to make, write it down, and decide which level of the Trust Hierarchy carries it. The pattern of answers tells you what work needs to happen before the campaign is allowed near a regulatory review.
| Claim type | Required carrier | Common failure mode |
|---|---|---|
| Outcome / efficacy claim | Level 2 (publication) supported by Level 1 (KOL) | Brand voice asserts the claim alone - KOLs distance themselves. |
| Mechanism / how-it-works claim | Level 2 + Level 5 with carefully bounded language | Brand voice over-simplifies, KOLs publicly correct. |
| Comparative claim vs. another product | Level 2 (head-to-head publication) - no exceptions | Comparative claim from Level 5 alone - regulatory action. |
| Patient-experience claim | Level 1 (peer clinician) + named patient consent | Brand-led testimonial without clinical sponsorship - appears manufactured. |
| Heritage / brand claim | Level 5 (brand voice) - appropriate | Over-promoting heritage as evidence - clinicians ignore. |
From the manuscript
The surgical navigation messaging house that survived three buyers.
A surgical navigation system needed to land three different messages with three very different buyers - surgeon, finance director, and procurement lead - without the brand contradicting itself across the three conversations. The default approach would have been three separate campaigns. The cost was prohibitive and the brand voice would have splintered.
The team built a single messaging house. At Level 2 sat the clinical efficacy publication. At Level 1 sat two named KOLs who had co-authored the publication and were comfortable speaking to it. From those two foundations, three audience cuts were derived - surgeon, finance director, procurement — each carrying claims appropriate to its trust level. None contradicted the others.
The campaign survived a regulatory review on first pass, a KOL push-back on the comparative claim (which had been anchored at Level 2 as required), and a procurement renegotiation that referenced the finance-director cut as evidence the brand had done its homework. The messaging house was the load-bearing artefact. Without it, the same creative would have been re-litigated three times - once per audience.
How AGENCY actually works with regulatory and KOLs
The process behind every claim that ships.
The regulatory and KOL choreography sits inside our standard creative process - the briefing form, the messaging house, the three-round amends cycle, the single source of truth. The Working with AGENCY brochure walks through how it lands in practice.
Want a pre-launch trust-hierarchy review?
Bring the campaign you’re about to ship, the claims it needs to make, and the KOLs who’ve been asked to back it. We’ll walk the trust hierarchy with you in 30 minutes and tell you which claims are safe and which ones will get pulled.